Opinion
Video
Author(s):
The panel discusses emerging therapies for Alzheimer disease that are currently in development, including donanemab, subcutaneous lecanemab, and ALZ-801.
Video content above is prompted by the following question(s):
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.